Overview: Phenylalanine Newborn Screen TestIntroduction: The Phenylalanine Newborn Screen Test measures phenylalanine to diagnose phenylketonuria (PKU), causing developmental delays. Following 2023 AAP guidelines, it uses biochemical methods for high specificity, supporting newborn screening. This test is critical for guiding early diagnosis, treatment planning, and improving outcomes in biochemistry for newborns with suspected PKU.
Other Names: Phenylalanine Assay, PKU Newborn Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: PKU screening began in the 1960s with Guthrie test development. Biochemical methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Measures phenylalanine to diagnose PKU, guides treatment, and evaluates newborns for developmental delays.
Test Parameters: 1. Phenylalanine Level
Pretest Condition: No fasting required. Collect dried blood spot or serum. Report family history of PKU or developmental issues.
Specimen: Dried Blood Spot (DBS Card, 3-5 spots), Serum (SST, 2-5 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document family history of PKU, developmental delays, or metabolic disorders. Include current feeding practices.
Consent: Written consent required, detailing the tests purpose, PKU implications, and risks of sample collection.
Procedural Considerations: Uses tandem mass spectrometry to measure phenylalanine levels. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for newborn PKU screening.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Recent feeding may elevate phenylalanine levels.
Clinical Significance: Elevated phenylalanine confirms PKU, guiding low-phenylalanine diet or therapy. Normal results may require confirmatory testing.
Specialist Consultation: Consult a pediatrician or metabolic specialist for result interpretation and treatment planning.
Additional Supporting Tests: PAH gene testing, tyrosine levels, or metabolic panel to confirm PKU diagnosis.
Test Limitations: False positives may occur; clinical correlation is needed. Sample quality affects sensitivity.
References: AAP Newborn Screening Guidelines, 2023; Pediatrics, Blau N, 2022.
